News

Singapore's Deputy Prime Minister Janil Puthucheary stated that the new tariffs imposed by the United States on pharmaceuticals may not have an "immediate impact" on Singapore's pharmaceutical companies. He also mentioned that Singapore might seek to set a cap on tariff rates, similar to agreements reached by Washington with other countries. Janil, who also serves as the Minister for Trade and Industry, told reporters on Saturday that most pharmaceutical companies in Singapore have established production capacity in the United States or have such plans. He indicated that this might shield them from the upcoming U.S. pharmaceutical tariffs, while companies are also seeking confirmation on whether they qualify for exemptions. Janil also noted that Singapore is in discussions with the U.S. government regarding semiconductor issues, but he declined to elaborate due to the confidentiality of the negotiations. "The models of the U.S. with South Korea, Japan, and the European Union are precedents that can be referenced," Janil said in response to questions about tariff caps. "As for whether it will be exactly the same, it will depend on discussions and negotiations between the U.S. and Singapore."